Review



vancomycin resistant enterococcus faecalis vre strains  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    ATCC vancomycin resistant enterococcus faecalis vre strains
    Minimum inhibitory concentrations (MICs, mg/L) against drug‐resistant S. aureus and E. faecalis strains.
    Vancomycin Resistant Enterococcus Faecalis Vre Strains, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 914 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vancomycin resistant enterococcus faecalis vre strains/product/ATCC
    Average 97 stars, based on 914 article reviews
    vancomycin resistant enterococcus faecalis vre strains - by Bioz Stars, 2026-03
    97/100 stars

    Images

    1) Product Images from "Compounds Containing 2,3‐Bis(phenylamino) Quinoxaline Exhibit Activity Against Methicillin‐Resistant Staphylococcus aureus , Enterococcus faecalis , and Their Biofilms"

    Article Title: Compounds Containing 2,3‐Bis(phenylamino) Quinoxaline Exhibit Activity Against Methicillin‐Resistant Staphylococcus aureus , Enterococcus faecalis , and Their Biofilms

    Journal: MicrobiologyOpen

    doi: 10.1002/mbo3.70011

    Minimum inhibitory concentrations (MICs, mg/L) against drug‐resistant S. aureus and E. faecalis strains.
    Figure Legend Snippet: Minimum inhibitory concentrations (MICs, mg/L) against drug‐resistant S. aureus and E. faecalis strains.

    Techniques Used:

    Minimum Inhibitory Concentrations (MICs, mg/l) of two selected compounds and four comparative agents against a panel of S. aureus (Panel A), E. faecalis (Panel B) and E. faecium (Panel C). Panel A ‐ All clinical strains of S. aureus (blue line), except for the final three standard S. aureus strains (ATCC 29213, ATCC 700698 and ATCC 700699, black line). MSSA = methicillin‐sensitive Staphylococcus aureus ; S = sensitive; GISA = glycopeptide‐intermediate S. aureus ; hGISA = hetero‐GISA; Panel B ‐ All clinical strains of E. faecalis (blue line), except for the final three ATCC/NTC strains (black line). VRE = vancomycin‐resistant enterococci; S = sensitive short for MSSA ‐ methicillin‐sensitive S. aureus ; Panel C ‐ VRE = vancomycin‐resistant enterococci; S = sensitive. Comparative agents: Van – Vancomycin; Lzd – Linezolid; Teic ‐ Teicoplanin; Dap – Daptomycin. A colour code was used based on the highest (in blue) to the lowest MIC value (in green) of the data set (the coloured bar, mg/l, is included on the left‐hand side of the picture). The highest range of the colour mapping was set to 2.00 (Panel A) or 4.00 (Panels B and C) for visualisation purposes.
    Figure Legend Snippet: Minimum Inhibitory Concentrations (MICs, mg/l) of two selected compounds and four comparative agents against a panel of S. aureus (Panel A), E. faecalis (Panel B) and E. faecium (Panel C). Panel A ‐ All clinical strains of S. aureus (blue line), except for the final three standard S. aureus strains (ATCC 29213, ATCC 700698 and ATCC 700699, black line). MSSA = methicillin‐sensitive Staphylococcus aureus ; S = sensitive; GISA = glycopeptide‐intermediate S. aureus ; hGISA = hetero‐GISA; Panel B ‐ All clinical strains of E. faecalis (blue line), except for the final three ATCC/NTC strains (black line). VRE = vancomycin‐resistant enterococci; S = sensitive short for MSSA ‐ methicillin‐sensitive S. aureus ; Panel C ‐ VRE = vancomycin‐resistant enterococci; S = sensitive. Comparative agents: Van – Vancomycin; Lzd – Linezolid; Teic ‐ Teicoplanin; Dap – Daptomycin. A colour code was used based on the highest (in blue) to the lowest MIC value (in green) of the data set (the coloured bar, mg/l, is included on the left‐hand side of the picture). The highest range of the colour mapping was set to 2.00 (Panel A) or 4.00 (Panels B and C) for visualisation purposes.

    Techniques Used: Glycoproteomics

    Pre‐exposure of S. aureus and E. faecalis to quinoxaline analogues decreases their sensitivities.
    Figure Legend Snippet: Pre‐exposure of S. aureus and E. faecalis to quinoxaline analogues decreases their sensitivities.

    Techniques Used: Analogues

    Pre‐exposure of S. aureus and E. faecalis to compounds 25 and 31 and impact on cross resistance to clinically available antibiotics.
    Figure Legend Snippet: Pre‐exposure of S. aureus and E. faecalis to compounds 25 and 31 and impact on cross resistance to clinically available antibiotics.

    Techniques Used:

    MBC values of compounds 25 and 31 against S. aureus and E. faecalis .
    Figure Legend Snippet: MBC values of compounds 25 and 31 against S. aureus and E. faecalis .

    Techniques Used:

    Quinoxaline analogues induce phenotypic alterations to the surface of both S. aureus and E. faecalis . Scanning electron micrographs of S. aureus ATCC 29213 (A–F) and E. faecalis NCTC 12201 (G–L). Panels A and G and Panels B and H represent untreated cells captured at 20,000‐ and 50,000‐times magnification, respectively. Bacteria treated with 2x MBC concentration of compound 25 are depicted in Panels C and I as well as Panels D and J at 20,000‐ and 50,000‐times magnification, respectively. Bacteria treated with 2 x MBC concentration of compound 31 are shown in Panels E and K as well as Panels F and L at 20,000‐ and 50,000‐times magnification, respectively. Blue arrows: loss of cellular content; red arrows: wrinkled cell surfaces; black arrow: cells that appear to have collapsed.
    Figure Legend Snippet: Quinoxaline analogues induce phenotypic alterations to the surface of both S. aureus and E. faecalis . Scanning electron micrographs of S. aureus ATCC 29213 (A–F) and E. faecalis NCTC 12201 (G–L). Panels A and G and Panels B and H represent untreated cells captured at 20,000‐ and 50,000‐times magnification, respectively. Bacteria treated with 2x MBC concentration of compound 25 are depicted in Panels C and I as well as Panels D and J at 20,000‐ and 50,000‐times magnification, respectively. Bacteria treated with 2 x MBC concentration of compound 31 are shown in Panels E and K as well as Panels F and L at 20,000‐ and 50,000‐times magnification, respectively. Blue arrows: loss of cellular content; red arrows: wrinkled cell surfaces; black arrow: cells that appear to have collapsed.

    Techniques Used: Analogues, Bacteria, Concentration Assay

    Quinoxaline analogues showed better anti‐biofilm activities (MBEC) compared to five selected comparative antibiotics.
    Figure Legend Snippet: Quinoxaline analogues showed better anti‐biofilm activities (MBEC) compared to five selected comparative antibiotics.

    Techniques Used: Analogues



    Similar Products

    vancomycin resistant enterococcus faecalis vre strains  (ATCC)
    97
    ATCC vancomycin resistant enterococcus faecalis vre strains
    Minimum inhibitory concentrations (MICs, mg/L) against drug‐resistant S. aureus and E. faecalis strains.
    Vancomycin Resistant Enterococcus Faecalis Vre Strains, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vancomycin resistant enterococcus faecalis vre strains/product/ATCC
    Average 97 stars, based on 1 article reviews
    vancomycin resistant enterococcus faecalis vre strains - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    vancomycin resistant enterococcus faecalis vre strain nj 3  (ATCC)
    99
    ATCC vancomycin resistant enterococcus faecalis vre strain nj 3
    Minimum inhibitory concentrations (MICs, mg/L) against drug‐resistant S. aureus and E. faecalis strains.
    Vancomycin Resistant Enterococcus Faecalis Vre Strain Nj 3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vancomycin resistant enterococcus faecalis vre strain nj 3/product/ATCC
    Average 99 stars, based on 1 article reviews
    vancomycin resistant enterococcus faecalis vre strain nj 3 - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    vancomycin resistant e faecalis vre strain v583  (ATCC)
    99
    ATCC vancomycin resistant e faecalis vre strain v583
    Overview of phage-antibiotic combinations tested against human pathogenic bacteria Δ .
    Vancomycin Resistant E Faecalis Vre Strain V583, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vancomycin resistant e faecalis vre strain v583/product/ATCC
    Average 99 stars, based on 1 article reviews
    vancomycin resistant e faecalis vre strain v583 - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Minimum inhibitory concentrations (MICs, mg/L) against drug‐resistant S. aureus and E. faecalis strains.

    Journal: MicrobiologyOpen

    Article Title: Compounds Containing 2,3‐Bis(phenylamino) Quinoxaline Exhibit Activity Against Methicillin‐Resistant Staphylococcus aureus , Enterococcus faecalis , and Their Biofilms

    doi: 10.1002/mbo3.70011

    Figure Lengend Snippet: Minimum inhibitory concentrations (MICs, mg/L) against drug‐resistant S. aureus and E. faecalis strains.

    Article Snippet: Compound 22 f displayed activities against Neisseria gonorrhoeae (ATCC 49226; MIC of 1 mg/l), one flucloxacillin‐resistant S. aureus strain ( S. aureus NCTC 12493; MIC = 1 mg/L) and two vancomycin‐resistant Enterococcus faecalis (VRE) strains (NCTC 12201 ‐ MIC = 0.250 mg/L and ATCC 51299 ‐ MIC = 2 mg/L).

    Techniques:

    Minimum Inhibitory Concentrations (MICs, mg/l) of two selected compounds and four comparative agents against a panel of S. aureus (Panel A), E. faecalis (Panel B) and E. faecium (Panel C). Panel A ‐ All clinical strains of S. aureus (blue line), except for the final three standard S. aureus strains (ATCC 29213, ATCC 700698 and ATCC 700699, black line). MSSA = methicillin‐sensitive Staphylococcus aureus ; S = sensitive; GISA = glycopeptide‐intermediate S. aureus ; hGISA = hetero‐GISA; Panel B ‐ All clinical strains of E. faecalis (blue line), except for the final three ATCC/NTC strains (black line). VRE = vancomycin‐resistant enterococci; S = sensitive short for MSSA ‐ methicillin‐sensitive S. aureus ; Panel C ‐ VRE = vancomycin‐resistant enterococci; S = sensitive. Comparative agents: Van – Vancomycin; Lzd – Linezolid; Teic ‐ Teicoplanin; Dap – Daptomycin. A colour code was used based on the highest (in blue) to the lowest MIC value (in green) of the data set (the coloured bar, mg/l, is included on the left‐hand side of the picture). The highest range of the colour mapping was set to 2.00 (Panel A) or 4.00 (Panels B and C) for visualisation purposes.

    Journal: MicrobiologyOpen

    Article Title: Compounds Containing 2,3‐Bis(phenylamino) Quinoxaline Exhibit Activity Against Methicillin‐Resistant Staphylococcus aureus , Enterococcus faecalis , and Their Biofilms

    doi: 10.1002/mbo3.70011

    Figure Lengend Snippet: Minimum Inhibitory Concentrations (MICs, mg/l) of two selected compounds and four comparative agents against a panel of S. aureus (Panel A), E. faecalis (Panel B) and E. faecium (Panel C). Panel A ‐ All clinical strains of S. aureus (blue line), except for the final three standard S. aureus strains (ATCC 29213, ATCC 700698 and ATCC 700699, black line). MSSA = methicillin‐sensitive Staphylococcus aureus ; S = sensitive; GISA = glycopeptide‐intermediate S. aureus ; hGISA = hetero‐GISA; Panel B ‐ All clinical strains of E. faecalis (blue line), except for the final three ATCC/NTC strains (black line). VRE = vancomycin‐resistant enterococci; S = sensitive short for MSSA ‐ methicillin‐sensitive S. aureus ; Panel C ‐ VRE = vancomycin‐resistant enterococci; S = sensitive. Comparative agents: Van – Vancomycin; Lzd – Linezolid; Teic ‐ Teicoplanin; Dap – Daptomycin. A colour code was used based on the highest (in blue) to the lowest MIC value (in green) of the data set (the coloured bar, mg/l, is included on the left‐hand side of the picture). The highest range of the colour mapping was set to 2.00 (Panel A) or 4.00 (Panels B and C) for visualisation purposes.

    Article Snippet: Compound 22 f displayed activities against Neisseria gonorrhoeae (ATCC 49226; MIC of 1 mg/l), one flucloxacillin‐resistant S. aureus strain ( S. aureus NCTC 12493; MIC = 1 mg/L) and two vancomycin‐resistant Enterococcus faecalis (VRE) strains (NCTC 12201 ‐ MIC = 0.250 mg/L and ATCC 51299 ‐ MIC = 2 mg/L).

    Techniques: Glycoproteomics

    Pre‐exposure of S. aureus and E. faecalis to quinoxaline analogues decreases their sensitivities.

    Journal: MicrobiologyOpen

    Article Title: Compounds Containing 2,3‐Bis(phenylamino) Quinoxaline Exhibit Activity Against Methicillin‐Resistant Staphylococcus aureus , Enterococcus faecalis , and Their Biofilms

    doi: 10.1002/mbo3.70011

    Figure Lengend Snippet: Pre‐exposure of S. aureus and E. faecalis to quinoxaline analogues decreases their sensitivities.

    Article Snippet: Compound 22 f displayed activities against Neisseria gonorrhoeae (ATCC 49226; MIC of 1 mg/l), one flucloxacillin‐resistant S. aureus strain ( S. aureus NCTC 12493; MIC = 1 mg/L) and two vancomycin‐resistant Enterococcus faecalis (VRE) strains (NCTC 12201 ‐ MIC = 0.250 mg/L and ATCC 51299 ‐ MIC = 2 mg/L).

    Techniques: Analogues

    Pre‐exposure of S. aureus and E. faecalis to compounds 25 and 31 and impact on cross resistance to clinically available antibiotics.

    Journal: MicrobiologyOpen

    Article Title: Compounds Containing 2,3‐Bis(phenylamino) Quinoxaline Exhibit Activity Against Methicillin‐Resistant Staphylococcus aureus , Enterococcus faecalis , and Their Biofilms

    doi: 10.1002/mbo3.70011

    Figure Lengend Snippet: Pre‐exposure of S. aureus and E. faecalis to compounds 25 and 31 and impact on cross resistance to clinically available antibiotics.

    Article Snippet: Compound 22 f displayed activities against Neisseria gonorrhoeae (ATCC 49226; MIC of 1 mg/l), one flucloxacillin‐resistant S. aureus strain ( S. aureus NCTC 12493; MIC = 1 mg/L) and two vancomycin‐resistant Enterococcus faecalis (VRE) strains (NCTC 12201 ‐ MIC = 0.250 mg/L and ATCC 51299 ‐ MIC = 2 mg/L).

    Techniques:

    MBC values of compounds 25 and 31 against S. aureus and E. faecalis .

    Journal: MicrobiologyOpen

    Article Title: Compounds Containing 2,3‐Bis(phenylamino) Quinoxaline Exhibit Activity Against Methicillin‐Resistant Staphylococcus aureus , Enterococcus faecalis , and Their Biofilms

    doi: 10.1002/mbo3.70011

    Figure Lengend Snippet: MBC values of compounds 25 and 31 against S. aureus and E. faecalis .

    Article Snippet: Compound 22 f displayed activities against Neisseria gonorrhoeae (ATCC 49226; MIC of 1 mg/l), one flucloxacillin‐resistant S. aureus strain ( S. aureus NCTC 12493; MIC = 1 mg/L) and two vancomycin‐resistant Enterococcus faecalis (VRE) strains (NCTC 12201 ‐ MIC = 0.250 mg/L and ATCC 51299 ‐ MIC = 2 mg/L).

    Techniques:

    Quinoxaline analogues induce phenotypic alterations to the surface of both S. aureus and E. faecalis . Scanning electron micrographs of S. aureus ATCC 29213 (A–F) and E. faecalis NCTC 12201 (G–L). Panels A and G and Panels B and H represent untreated cells captured at 20,000‐ and 50,000‐times magnification, respectively. Bacteria treated with 2x MBC concentration of compound 25 are depicted in Panels C and I as well as Panels D and J at 20,000‐ and 50,000‐times magnification, respectively. Bacteria treated with 2 x MBC concentration of compound 31 are shown in Panels E and K as well as Panels F and L at 20,000‐ and 50,000‐times magnification, respectively. Blue arrows: loss of cellular content; red arrows: wrinkled cell surfaces; black arrow: cells that appear to have collapsed.

    Journal: MicrobiologyOpen

    Article Title: Compounds Containing 2,3‐Bis(phenylamino) Quinoxaline Exhibit Activity Against Methicillin‐Resistant Staphylococcus aureus , Enterococcus faecalis , and Their Biofilms

    doi: 10.1002/mbo3.70011

    Figure Lengend Snippet: Quinoxaline analogues induce phenotypic alterations to the surface of both S. aureus and E. faecalis . Scanning electron micrographs of S. aureus ATCC 29213 (A–F) and E. faecalis NCTC 12201 (G–L). Panels A and G and Panels B and H represent untreated cells captured at 20,000‐ and 50,000‐times magnification, respectively. Bacteria treated with 2x MBC concentration of compound 25 are depicted in Panels C and I as well as Panels D and J at 20,000‐ and 50,000‐times magnification, respectively. Bacteria treated with 2 x MBC concentration of compound 31 are shown in Panels E and K as well as Panels F and L at 20,000‐ and 50,000‐times magnification, respectively. Blue arrows: loss of cellular content; red arrows: wrinkled cell surfaces; black arrow: cells that appear to have collapsed.

    Article Snippet: Compound 22 f displayed activities against Neisseria gonorrhoeae (ATCC 49226; MIC of 1 mg/l), one flucloxacillin‐resistant S. aureus strain ( S. aureus NCTC 12493; MIC = 1 mg/L) and two vancomycin‐resistant Enterococcus faecalis (VRE) strains (NCTC 12201 ‐ MIC = 0.250 mg/L and ATCC 51299 ‐ MIC = 2 mg/L).

    Techniques: Analogues, Bacteria, Concentration Assay

    Quinoxaline analogues showed better anti‐biofilm activities (MBEC) compared to five selected comparative antibiotics.

    Journal: MicrobiologyOpen

    Article Title: Compounds Containing 2,3‐Bis(phenylamino) Quinoxaline Exhibit Activity Against Methicillin‐Resistant Staphylococcus aureus , Enterococcus faecalis , and Their Biofilms

    doi: 10.1002/mbo3.70011

    Figure Lengend Snippet: Quinoxaline analogues showed better anti‐biofilm activities (MBEC) compared to five selected comparative antibiotics.

    Article Snippet: Compound 22 f displayed activities against Neisseria gonorrhoeae (ATCC 49226; MIC of 1 mg/l), one flucloxacillin‐resistant S. aureus strain ( S. aureus NCTC 12493; MIC = 1 mg/L) and two vancomycin‐resistant Enterococcus faecalis (VRE) strains (NCTC 12201 ‐ MIC = 0.250 mg/L and ATCC 51299 ‐ MIC = 2 mg/L).

    Techniques: Analogues

    Overview of phage-antibiotic combinations tested against human pathogenic bacteria Δ .

    Journal: Frontiers in Cellular and Infection Microbiology

    Article Title: Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy

    doi: 10.3389/fcimb.2019.00022

    Figure Lengend Snippet: Overview of phage-antibiotic combinations tested against human pathogenic bacteria Δ .

    Article Snippet: A phage cocktail consisting of the two phages EFDG1 and EFLK1 ( Myoviridae ), was used in combination with ampicillin for treatment of septic peritonitis in a mouse model with the vancomycin resistant E. faecalis (VRE) strain V583, also referred to as ATCC 700802 (Gelman et al., ).

    Techniques: